Abstract
Honokiol (3’,5-di-(2-propenyl)-1,1’-biphenyl-2,4’-diol) is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models. Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-κB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression. Furthermore, pharmacokinetic profile of honokiol has revealed a desirable spectrum of bioavailability after intravenous administration in animal models, thus making it a suitable agent for clinical trials. In this review, we discuss recent data describing the molecular targets of honokiol and its anti-cancer activities against various malignancies in pre-clinical models. Evaluation of honokiol in clinical trials will be the next step towards its possible human applications.
Keywords: Honokiol, chemoprevention, chemotherapy, natural agent, Magnolia, traditional Chinese medicine, cancer, aspirin, taxol, natural products, anti-tumor activity, carcinoma, cytotoxicity, human myelogenous leukemia, adenocarcinoma
Current Molecular Medicine
Title:Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy
Volume: 12 Issue: 10
Author(s): S. Arora, S. Singh, G.A. Piazza, C.M. Contreras, J. Panyam and A.P. Singh
Affiliation:
Keywords: Honokiol, chemoprevention, chemotherapy, natural agent, Magnolia, traditional Chinese medicine, cancer, aspirin, taxol, natural products, anti-tumor activity, carcinoma, cytotoxicity, human myelogenous leukemia, adenocarcinoma
Abstract: Honokiol (3’,5-di-(2-propenyl)-1,1’-biphenyl-2,4’-diol) is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models. Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-κB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression. Furthermore, pharmacokinetic profile of honokiol has revealed a desirable spectrum of bioavailability after intravenous administration in animal models, thus making it a suitable agent for clinical trials. In this review, we discuss recent data describing the molecular targets of honokiol and its anti-cancer activities against various malignancies in pre-clinical models. Evaluation of honokiol in clinical trials will be the next step towards its possible human applications.
Export Options
About this article
Cite this article as:
Arora S., Singh S., Piazza G.A., Contreras C.M., Panyam J. and Singh A.P., Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy, Current Molecular Medicine 2012; 12 (10) . https://dx.doi.org/10.2174/156652412803833508
DOI https://dx.doi.org/10.2174/156652412803833508 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploiting Internal Ribosome Entry Sites in Gene Therapy Vector Design
Current Gene Therapy Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging The Immunopathology of Tuberculosis – An Update
Current Respiratory Medicine Reviews Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer
Current Cancer Drug Targets Novel Derivatives of Benfluron and Dimefluron Synthesis and Anticancer activity
Letters in Drug Design & Discovery Interactions Between Probiotic Dairy Propionibacteria and the Intestinal Epithelium
Current Immunology Reviews (Discontinued) Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology The Metabolite Trimethylamine-N-Oxide is an Emergent Biomarker of Human Health
Current Medicinal Chemistry An Integrated and Disease-Oriented Growth Factor-Regulated Signal Transduction Network
Current Molecular Medicine Deacetylase Inhibitors Modulate the Myostatin/Follistatin Axis without Improving Cachexia in Tumor-Bearing Mice
Current Cancer Drug Targets Synthesis, Molecular Docking, in vitro Antiproliferative and Antioxidant Activity of Novel Pyrrolidinyl-Carbazole Derivatives
Current Organic Synthesis Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Diagnosis and Treatment of Breast, Ovarian and Cervical Cancers
Current Drug Metabolism Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Application of Alphaviral Vectors for Immunomodulation in Cancer Therapy
Current Pharmaceutical Design Artepillin C: A Review
Letters in Drug Design & Discovery NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry The Role of Apoptotic Dysfunction in the Pathogenesis of Endometriosis
Current Women`s Health Reviews The Warburg Effect on Cancer Cells Survival: The Role of Sugar Starvation in Cancer Therapy
Current Reviews in Clinical and Experimental Pharmacology Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science